GlassScriptPhysician profile
Betty Yu
NPI 1760960769
$8,065.47
in general payments reported to CMS, 2019-2025
29 companies · $636 in 2025
The $636 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,106 · 2022: $2,154 · 2023: $1,171 · 2024: $998 · 2025: $636.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,696 · Education: $109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,696.30 |
| Education | $109.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,063.25 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $985.10 | 2021-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Sunovion Pharmaceuticals INC. | $831.99 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $829.66 | 2021-2024 | Austedo Xr, Austedo, Uzedy |
| Alkermes, INC. | $804.91 | 2021-2024 | Aristada, Lybalvi, Vivitrol |
| Abbvie INC. | $792.10 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $499.19 | 2021-2023 | Invega Sustenna, Spravato |
| Neurocrine Biosciences, INC. | $470.49 | 2021-2024 | Ingrezza |
| Lundbeck LLC | $408.41 | 2021-2025 | Rexulti |
| Axsome Therapeutics, INC. | $200.76 | 2023-2025 | Auvelity, Sunosi |
| Corium, LLC | $195.42 | 2022-2024 | Azstarys |
| Vanda Pharmaceuticals INC. | $178.25 | 2025 | Fanapt |
| Tempus Ai, INC | $135.43 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $128.27 | 2021-2022 | |
| Indivior INC. | $94.39 | 2021-2024 | Sublocade |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $87.51 | 2021-2022 | |
| Orexo US, INC. | $69.99 | 2021-2024 | Zubsolv |
| E.R. Squibb & Sons, L.L.C. | $52.18 | 2025 | Cobenfy |
| Bausch Health US, LLC | $34.36 | 2022-2023 | Aplenzin |
| Almatica Pharma LLC | $32.96 | 2022 | |
| Supernus Pharmaceuticals, INC. | $32.13 | 2022 | |
| Idorsia Pharmaceuticals US INC | $24.09 | 2022 | |
| Tris Pharma INC | $22.83 | 2025 | Dyanavel Xr |
| Pear Therapeutics (US), INC. | $19.41 | 2021 | |
| Neos Therapeutics, LP | $18.99 | 2024 | Adzenys Xr-Odt |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.93 | 2023 | Xifaxan |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $15.23 | 2025 | Rexulti |
| Arbor Pharmaceuticals, INC. | $14.24 | 2021 | |
| Genentech USA, INC. | $5.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Betty Yu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.